专注于创新型疫苗研究的康希诺生物股份公司8月13日成功登陆科创板。
康希诺于今年1月按照第五套上市标准递交科创板上市申请，募集资金拟用于新型疫苗产能扩大与疫苗产品研发。康希诺生物也是首批按照香港联交所18A章上市的H股公司之一。
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
